FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3127834374> ?p ?o ?g. }

• W3127834374 endingPage "e1003495" @default.
• W3127834374 startingPage "e1003495" @default.
• W3127834374 abstract "MB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted a Phase I clinical trial to assess the safety, pharmacokinetics (PK), and ex vivo efficacy of single and repeated doses of MB66 when used intravaginally.The clinical trial enrolled healthy reproductive-aged, sexually abstinent women. In Segment A, 9 women received a single MB66 film which was inserted into the vaginal posterior fornix by a clinician. In Segment B, 29 women were randomly assigned to MB66 (Active) or Placebo film groups and were instructed to insert 1 film vaginally for 7 consecutive days. Visits and clinical sampling occurred predose and at various time points after single and repeated film doses. The primary endpoint was number of adverse events (AEs) Grade 2 or higher related to product use. Secondary endpoints included film dissolution rate, Nugent score (a Gram stain scoring system to diagnose bacterial vaginosis), vaginal pH, post-use survey results, cytokine concentrations in cervicovaginal lavage (CVL) specimens (assessed by Luminex assay), mAb concentrations in vaginal fluid collected from 4 sites (assessed by ELISA), and HIV and HSV neutralization activity of CVL samples ex vivo (assessed by TZM-bl and plaque reduction assay, respectively). The product was generally safe and well tolerated, with no serious AEs recorded in either segment. The AEs in this study were primarily genitourinary in nature with the most commonly reported AE being asymptomatic microscopic hematuria. There were no differences in vaginal pH or Nugent scores or significant increases in levels of proinflammatory cytokines for up to 7 days after film insertion in either segment or between Active and Placebo groups. Acceptability and willingness to use the product were judged to be high by post-use surveys. Concentrations of VRC01-N and HSV8-N in vaginal secretions were assessed over time to generate pharmacokinetic curves. Antibody levels peaked 1 hour postdosing with Active film (median: 35 μg/mL) and remained significantly elevated at 24 hours post first and seventh film (median: 1.8 μg/mL). Correcting for sample dilution (1:20), VRC01-N concentrations ranged from 36 to 700 μg/mL at the 24-hour time point, greater than 100-fold the IC50 for VRC01 (0.32 μg/mL); HSV8-N concentrations ranged from 80 to 601 μg/mL, well above the IC50 of 0.1 μg/m. CVL samples collected 24 hours after MB66 insertion significantly neutralized both HIV-1 and HSV-2 ex vivo. Study limitations include the small size of the study cohort, and the fact that no samples were collected between 24 hours and 7 days for pharmacokinetic evaluation.Single and repeated intravaginal applications of MB66 film were safe, well tolerated, and acceptable. Concentrations and ex vivo bioactivity of both mAbs in vaginal secretions were significantly elevated and thus could provide protection for at least 24 hours postdose. However, further research is needed to evaluate the efficacy of MB66 film in women at risk for HIV and HSV infection. Additional antibodies could be added to this platform to provide protection against other sexually transmitted infections (STIs) and contraception.ClinicalTrials.gov NCT02579083." @default.
• W3127834374 created "2021-02-15" @default.
• W3127834374 creator A5006144681 @default.
• W3127834374 creator A5007044548 @default.
• W3127834374 creator A5025150770 @default.
• W3127834374 creator A5025746769 @default.
• W3127834374 creator A5028131735 @default.
• W3127834374 creator A5037091167 @default.
• W3127834374 creator A5037704787 @default.
• W3127834374 creator A5038522202 @default.
• W3127834374 creator A5041943592 @default.
• W3127834374 creator A5060237704 @default.
• W3127834374 creator A5079140140 @default.
• W3127834374 creator A5080688116 @default.
• W3127834374 creator A5089328104 @default.
• W3127834374 creator A5090712111 @default.
• W3127834374 date "2021-02-03" @default.
• W3127834374 modified "2023-10-10" @default.
• W3127834374 title "Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial" @default.
• W3127834374 cites W1868667984 @default.
• W3127834374 cites W1990798154 @default.
• W3127834374 cites W1992566288 @default.
• W3127834374 cites W1993023130 @default.
• W3127834374 cites W2000534965 @default.
• W3127834374 cites W2002116187 @default.
• W3127834374 cites W2005311204 @default.
• W3127834374 cites W2020162541 @default.
• W3127834374 cites W2025695181 @default.
• W3127834374 cites W2035118667 @default.
• W3127834374 cites W2036479803 @default.
• W3127834374 cites W2037062496 @default.
• W3127834374 cites W2041763617 @default.
• W3127834374 cites W2044369525 @default.
• W3127834374 cites W2054233015 @default.
• W3127834374 cites W2054264693 @default.
• W3127834374 cites W2068519203 @default.
• W3127834374 cites W2080499742 @default.
• W3127834374 cites W2094976697 @default.
• W3127834374 cites W2113236498 @default.
• W3127834374 cites W2121558572 @default.
• W3127834374 cites W2127938365 @default.
• W3127834374 cites W2128556228 @default.
• W3127834374 cites W2130356829 @default.
• W3127834374 cites W2135151522 @default.
• W3127834374 cites W2135483305 @default.
• W3127834374 cites W2140817741 @default.
• W3127834374 cites W2142874808 @default.
• W3127834374 cites W2146634980 @default.
• W3127834374 cites W2163488022 @default.
• W3127834374 cites W2170781618 @default.
• W3127834374 cites W2171322382 @default.
• W3127834374 cites W2178622748 @default.
• W3127834374 cites W2211567330 @default.
• W3127834374 cites W2290010664 @default.
• W3127834374 cites W2540893967 @default.
• W3127834374 cites W2611116815 @default.
• W3127834374 cites W2765304199 @default.
• W3127834374 cites W2765318872 @default.
• W3127834374 cites W2768623425 @default.
• W3127834374 cites W2773592460 @default.
• W3127834374 cites W2794415141 @default.
• W3127834374 cites W2799658084 @default.
• W3127834374 cites W2964676689 @default.
• W3127834374 cites W2982324818 @default.
• W3127834374 cites W30316958 @default.
• W3127834374 cites W3034991629 @default.
• W3127834374 cites W578092267 @default.
• W3127834374 doi "https://doi.org/10.1371/journal.pmed.1003495" @default.
• W3127834374 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7857576" @default.
• W3127834374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33534791" @default.
• W3127834374 hasPublicationYear "2021" @default.
• W3127834374 type Work @default.
• W3127834374 sameAs 3127834374 @default.
• W3127834374 citedByCount "27" @default.
• W3127834374 countsByYear W31278343742021 @default.
• W3127834374 countsByYear W31278343742022 @default.
• W3127834374 countsByYear W31278343742023 @default.
• W3127834374 crossrefType "journal-article" @default.
• W3127834374 hasAuthorship W3127834374A5006144681 @default.
• W3127834374 hasAuthorship W3127834374A5007044548 @default.
• W3127834374 hasAuthorship W3127834374A5025150770 @default.
• W3127834374 hasAuthorship W3127834374A5025746769 @default.
• W3127834374 hasAuthorship W3127834374A5028131735 @default.
• W3127834374 hasAuthorship W3127834374A5037091167 @default.
• W3127834374 hasAuthorship W3127834374A5037704787 @default.
• W3127834374 hasAuthorship W3127834374A5038522202 @default.
• W3127834374 hasAuthorship W3127834374A5041943592 @default.
• W3127834374 hasAuthorship W3127834374A5060237704 @default.
• W3127834374 hasAuthorship W3127834374A5079140140 @default.
• W3127834374 hasAuthorship W3127834374A5080688116 @default.
• W3127834374 hasAuthorship W3127834374A5089328104 @default.
• W3127834374 hasAuthorship W3127834374A5090712111 @default.
• W3127834374 hasBestOaLocation W31278343741 @default.
• W3127834374 hasConcept C112705442 @default.
• W3127834374 hasConcept C126322002 @default.
• W3127834374 hasConcept C141071460 @default.
• W3127834374 hasConcept C142724271 @default.
• W3127834374 hasConcept C150903083 @default.

• next